Kazia Therapeutics Announces Registered Direct Offering
Ticker: KZIA · Form: 6-K · Filed: Jan 13, 2025 · CIK: 1075880
| Field | Detail |
|---|---|
| Company | Kazia Therapeutics LTD (KZIA) |
| Form Type | 6-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | medium |
| Pages | 7 |
| Reading Time | 9 min |
| Key Dollar Amounts | $1.50, $1.4999, $0.0001, $1.7 m, $70,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: offering, capital-raise, securities
TL;DR
Kazia Therapeutics is doing a stock offering, details TBD.
AI Summary
On January 10, 2025, Kazia Therapeutics Limited entered into a securities purchase agreement with an institutional investor for a registered direct offering and private placement. The filing does not specify the dollar amounts or the exact terms of the offering.
Why It Matters
This filing indicates Kazia Therapeutics is raising capital through a securities offering, which could fund its ongoing research and development efforts.
Risk Assessment
Risk Level: medium — The company is raising capital, which can be positive, but the lack of specific financial details in this initial report introduces uncertainty.
Key Players & Entities
- Kazia Therapeutics Limited (company) — Registrant
- January 10, 2025 (date) — Date of securities purchase agreement
FAQ
What is the total amount Kazia Therapeutics aims to raise in this offering?
The filing does not specify the total amount to be raised in the registered direct offering and private placement.
Who is the institutional investor involved in the purchase agreement?
The filing refers to 'an institutional investor' but does not name the specific entity.
What is the expected closing date for the securities purchase agreement?
The filing does not provide an expected closing date for the transaction.
What are the terms of the private placement mentioned in the filing?
The filing states that a private placement is occurring concurrently but does not detail its specific terms.
What is the purpose of this registered direct offering and private placement?
The filing does not explicitly state the purpose of the capital raise, but it is typical for funding research and development.
Filing Stats: 2,136 words · 9 min read · ~7 pages · Grade level 15.4 · Accepted 2025-01-13 08:03:00
Key Financial Figures
- $1.50 — of the Company, at a purchase price of $1.50 per ADS, and (ii) pre-funded warrants (
- $1.4999 — to 779,893 ADSs, at a purchase price of $1.4999 per Pre-Funded Warrant to purchase one
- $0.0001 — ble for one ADS at an exercise price of $0.0001 per ADS, is immediately exercisable, an
- $1.7 m — rom the Offerings will be approximately $1.7 million, after deducting placement agents
- $70,000 — al counsel up to an aggregate amount of $70,000. Pursuant to the Placement Agency Agr
- $1,734,081 — the ATM Prospectus Supplement to up to $1,734,081 of ADSs, effective as of January 10, 20
- $1,634,291 — ary 10, 2025, after taking into account $1,634,291 of ADSs that the Company has previously
- $99,790 — the Company may offer up to additional $99,790 of ADSs (the Current Limit) under the A
Filing Documents
- d868096d6k.htm (6-K) — 27KB
- d868096dex41.htm (EX-4.1) — 83KB
- d868096dex42.htm (EX-4.2) — 89KB
- d868096dex43.htm (EX-4.3) — 89KB
- d868096dex44.htm (EX-4.4) — 17KB
- d868096dex51.htm (EX-5.1) — 62KB
- d868096dex52.htm (EX-5.2) — 12KB
- d868096dex101.htm (EX-10.1) — 189KB
- d868096dex102.htm (EX-10.2) — 51KB
- d868096dex991.htm (EX-99.1) — 10KB
- g868096g0110115022617.jpg (GRAPHIC) — 3KB
- g868096g0110191410425.jpg (GRAPHIC) — 3KB
- g868096g0110191834336.jpg (GRAPHIC) — 7KB
- 0001193125-25-005004.txt ( ) — 649KB
Forward-Looking Statements
Forward-Looking Statements This Report of Foreign Private Issuer on Form 6-K may contain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which can generally be identified as such by the use of words such as may, will, estimate, future, forward, anticipate, or other similar words. Any statement describing Kazias future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking expectations, plans and prospects. Such statements are based on Kazias current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: related to market and other conditions, associated with clinical and preclinical trials and product development, including the risk that preliminary or interim data may not reflect final results, related to regulatory approvals, and related to the impact of global economic conditions. These and other risks and uncertainties are described more fully in Kazias Annual Report, filed on form 20-F with the SEC, and in subsequent filings with the SEC. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. Investors should not place undue reliance on these forward-looking statements, which apply only as of the date of this Report of Foreign Private Issuer on Form 6-K. EXHIBIT LIST Exhibit Description 4.1 For